NEW YORK, NY--(Marketwire -09/04/12)- Immunovative, Inc. ("IMUN" or the "Company") (IMUN) (IMUN) announces today that Immunovative Therapies, Ltd. ("ITL") has made appointments to its Scientific Advisory Board ("SAB") which is Chaired by Dr. Emmanuel Katsanis, MD, Chief Medical Officer of ITL and the Louise Thomas Chair in Pediatric Cancer Research; Professor, Pediatrics, Medicine Pathology and Immunobiology; Director, of the University of Arizona Blood and Marrow Transplantation Program; Associate Chair for Research, Department of Pediatrics; and Head, Division of Pediatric Hematology/Oncology.
The SAB serves as a Committee to the ITL Board of Directors and serves the joint interests of IMUN and ITL. Dr. Laurence Rulleau, PhD, a member of the IMUN Business Advisory Board, will represent IMUN at ITL SAB meetings.
Joining Dr. Rulleau and Dr. Katsanis, are five world-renowned medical scientists who bring expertise in key areas that will be invaluable in transitioning ITL from the current clinical development phase to commercialization.
The members of the Scientific Advisory Board are:
Lawrence Fong, MD, Associate Professor of Medicine, Division of Hematology/Oncology at the University of California, San Francisco. Dr. Fong is a specialist in urologic oncology and an expert in tumor immunology and developing cancer vaccines.
Diego Martin, MD, PhD, Professor of Radiology and Head of the Department of Medical Imaging at the University of Arizona. Dr. Martin is an internationally recognized leader in MRI technology for the diagnosis and monitoring of disease.
Frank Ondrey, MD, PhD, Associate Professor of Medicine and Director of the Molecular Oncology Program at the University of Minnesota. Dr. Ondrey is a head and neck cancer surgeon board certified in otolaryngology.
Antoni Ribas, MD, PhD, Professor of Medicine, Hematology/Oncology, Surgical Oncology and Director of the Cell and Gene Therapy Core Facility at the University of California, Los Angeles. Dr. Ribas is a specialist in tumor immunology and cancer vaccine development and clinical trials in immunotherapy.
Theresa Whiteside, PhD, Professor of Pathology, Immunology and Otolaryngology at University of Pittsburgh School of Medicine. Dr. Whiteside serves as Laboratory Director of Immunologic Monitoring and Cellular Products Laboratory at University of Pittsburgh Cancer Institute.
"We are very pleased to bring together these key thought leaders to establish the Immunovative Therapies, Ltd. Scientific Advisory Board," stated Dr. Emmanuel Katsanis, Immunovative's Chief Medical Officer. "Their deep insight into immunological mechanisms of cancer, the design, analysis, imaging, pathological and immunological monitoring of clinical trials will be instrumental in advancing and expanding our therapeutic programs."
Dr. Michael Har-Noy, Founder and CEO of Immunovative Therapies, stated: "We are honored and humbled that our technology is able to attract the interest and direct participation of these world class scientists and physicians on our SAB. We anticipate an active SAB and look forward to working closely with these experts in developing the strategies that will enable us to advance our immunotherapies and understand how they are working and how to improve them in order to provide patients with advanced cancer with alternatives to toxic treatment regimens. "
"During the past year, ITL has made important advances in the development of cell-based immunotherapy products," said Seth Shaw, CEO and Chairman of IMUN. "Preparations are now almost completed for launch of a randomized, controlled, Phase II/III clinical of the lead AlloStim™ product in advanced stages of metastatic breast cancer and for launch of a randomized Phase I/II clinical trial of AlloVax™ in advanced stages of Head and Neck cancer. The appointment of the SAB will be invaluable in overseeing the scientific analysis of data from these trials and in developing new products and improvements. The SAB will also assist in supporting our strategy to collaborate with academic medical centers to develop additional indications of AlloStim™ and AlloVax™ and in seeking and evaluating potential licensing partners."
About Immunovative, Inc.:
On December 12th, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. Please visit IMUN's website at www.imun.com
About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israeli Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israeli technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit ITL's website at: www.immunovative.co.il
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.
Mr. Seth Shaw
Chairman & Chief Executive Officer
New York: +1-917-796-9926
Email: Email Contact